As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive ...

A newly developed laboratory tool can, within hours, help to identify specific viruses which can be used to destroy variants ...

Recent worldwide emergence of CA-MRSA has prompted the development of several new antibiotics (see Table 2). In the past, as vancomycin became less effective against MRSA, clinicians turned to ...

A mom has said her 11-day-old daughter died from an infection at an 'absolutely putrid' hospital at an inquiry into the newborn's April 2017 death, per reports.

Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development. Basilea secured the license ...

MRSA - or methicillin resistant staphylococcus aureus - has already become resistant to most common antibiotics, making it difficult to treat with drugs. Once it gets into the body, through wounds ...

The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole's revenues, currently a minor part of its CHF 131 million ($137 million ...

aureus (MRSA). The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole’s revenues, according to analysts. In 2023 ...

Testing market is projected to grow from USD 4.3 billion in 2025 to USD 6.5 billion by 2035, registering a CAGR of 4.2%. The ...

The researchers brought their labs together to conduct a study with antibiotics in a diabetic mouse model of the Staph infection. First, they prepared a mouse model with bacterial infection in the ...